A. Ferrajoli

M. Suarez‐Almazor, L. Ramondetta, S. Giordano, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.

E. Estey, Z. Estrov, D. Harris, 1992, Blood.

Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures

Z. Estrov, J. Burger, W. Wierda, 2022, Leukemia.

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

Z. Estrov, D. Harris, R. Başar, 2018, Leukemia.

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, M. Keating, 2017, Leukemia.

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

B. Goh, M. Konopleva, Z. Estrov, 2017, Cancer.

Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets

J. Lillard, S. Kornblau, Y. Qiu, 2022, Blood cancer journal.

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

α chromosome-positive chronic myeloid leukemia after failure of interferon- Result of high-dose imatinib mesylate in patients with Philadelphia

G. Garcia-Manero, S. Verstovsek, E. Freireich, 2013 .

Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2003, Cancer.

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.

T. Kadia, F. Ravandi, N. Pemmaraju, 2017, Hematology/oncology and stem cell therapy.

Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms.

R. Kanagal-Shamanna, L. Medeiros, J. Jorgensen, 2014, Archives of pathology & laboratory medicine.

Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study

M. Suarez‐Almazor, E. Sturgis, E. Hawk, 2020, Supportive Care in Cancer.

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, P. Jain, 2014, Cancer.

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Leukemia & lymphoma.

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib

G. Daley, H. Kantarjian, J. Cortes, 2007, Cancer.

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, British journal of haematology.

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

H. Kantarjian, J. Cortes, S. Verstovsek, 2004, Blood.

The Role of Monoclonal Antibodies in the Management of Leukemia

A. Ferrajoli, A. Al-Kali, M. Cherry, 2010, Pharmaceuticals.

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

A. Rosenwald, H. Kantarjian, Xuelin Huang, 2014, The Lancet. Oncology.

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2013, American journal of hematology.

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

M. Konopleva, Z. Estrov, H. Kantarjian, 2017 .

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, American journal of hematology.

Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

H. Kantarjian, F. Ravandi, S. Pierce, 2011, Blood.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, The Lancet. Oncology.

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2009, Cancer.

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2011, Clinical lymphoma, myeloma & leukemia.

BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?

A. Ferrajoli, S. Venugopal, S. Desikan, 2022, Expert review of hematology.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Blood.

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.

Z. Estrov, R. Kurzrock, T. Manshouri, 2002, Blood.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Z. Estrov, R. Kurzrock, T. Manshouri, 2002 .

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2010, British journal of haematology.

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

G. Gordon, H. Kantarjian, G. Garcia-Manero, 2005, Clinical Cancer Research.

Phase1Study of ABT-751, a NovelMicrotubule Inhibitor, in Patients with Refractory HematologicMalignancies

G. Gordon, H. Kantarjian, G. Garcia-Manero, 2005 .

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.

Z. Estrov, D. Harris, H. Kantarjian, 2007, Cancer research.

WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).

Z. Estrov, D. Harris, W. Priebe, 2005, Anticancer research.

Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis

Z. Estrov, R. Kurzrock, M. Talpaz, 1993, Stem cells.

Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia

K. Stamatopoulos, Z. Estrov, M. Keating, 2017, Haematologica.

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte‐macrophage–colony stimulating factor (GM‐CSF) alternating with methotrexate and cytarabine plus rituximab and GM‐CSF in patients with Richter syndrome or fludarabine‐refractory chroni

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

E. Kimby, J. Gribben, F. Bosch, 2012, Leukemia & lymphoma.

First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia.

H. Kantarjian, E. Jabbour, S. Konoplev, 2018, JCO precision oncology.

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

H. Kantarjian, J. Cortes, D. McConkey, 2011, Clinical lymphoma, myeloma & leukemia.

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, M. Keating, 2008, Cancer.

Prognostic Factors in the Era of Targeted Therapies in CLL

A. Ferrajoli, P. Boddu, 2018, Current Hematologic Malignancy Reports.

The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

Z. Estrov, H. Kantarjian, J. Cortes, 2018, British journal of haematology.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

T. Shanafelt, C. Fegan, D. Rossi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD 49 d Is the Strongest Flow Cytometry – Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia

T. Shanafelt, C. Fegan, D. Rossi, 2014 .

The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

L. Abruzzo, M. Keating, S. O'brien, 2012, Cancer.

The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide

Z. Estrov, D. Harris, R. Başar, 2018, Front. Immunol..

Brief report Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans

L. Rassenti, T. Kipps, S. Slager, 2012 .

Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets

J. Lillard, S. Kornblau, Y. Qiu, 2021, Blood Cancer Journal.

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

M. Keating, S. O'brien, J. Burger, 2014, Haematologica.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

P. A. Futreal, Z. Estrov, H. Kantarjian, 2019, Blood advances.

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments

Z. Estrov, M. Routbort, K. Patel, 2019, British journal of haematology.

Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

Z. Estrov, H. Kantarjian, P. Jain, 2017, Cancer.

Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex

Z. Estrov, D. Harris, P. Jain, 2017, Molecular Cancer Research.

Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic

M. Fabbri, G. Calin, A. Cimmino, 2020, Frontiers in Oncology.

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia

Z. Estrov, H. Kantarjian, J. Cortes, 2018, Cancer.

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations.

H. Kantarjian, M. Keating, J. Burger, 2021, Blood.

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2004 .

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.

H. Kantarjian, J. Cortes, P. Jain, 2015, The Lancet. Haematology.

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

R. Kurzrock, J. Cortes, M. Keating, 2003, Cancer.

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.

H. Kantarjian, J. Cortes, M. Keating, 2004 .

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

H. Kantarjian, J. Cortes, M. Keating, 2003, Cancer.

Unusual complications in the management of chronic lymphocytic leukemia

A. Ferrajoli, M. Gordon, 2022 .

myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute

Z. Estrov, J. Cortes, S. Verstovsek, 2013 .

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2006, British journal of haematology.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy

A. Krohn-Grimberghe, C. Bokemeyer, Z. Estrov, 2017, Oncoimmunology.

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, P. Jain, 2018, Oncotarget.

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, S. Verstovsek, 2016, The Journal of Immunology.

Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.

Z. Estrov, D. Harris, H. Kantarjian, 2007, Leukemia research.

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Current guidelines in defining therapeutic strategies.

M. Keating, A. Ferrajoli, 2004, Hematology/oncology clinics of North America.

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Z. Estrov, M. Andreeff, H. Kantarjian, 2019, Blood.

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia

Z. Estrov, H. Kantarjian, P. Jain, 2016, Clinical Cancer Research.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

Z. Estrov, A. Wiestner, M. Keating, 2016, Haematologica.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

H. Kantarjian, M. Keating, S. O'brien, 2011, Blood.

Postsplenectomy Cytomegaloviral Mononucleosis

P. Lin, H. Amin, A. Ferrajoli, 2005 .

Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response.

H. Amin, A. Ferrajoli, Xiang Y. Han, 2005, American journal of clinical pathology.

Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

S. Sabbioni, G. Calin, M. Negrini, 2015, EBioMedicine.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.

H. Kantarjian, J. Reuben, Hui Gao, 2013, Blood.

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

H. Kantarjian, A. Tsimberidou, S. O'brien, 2007, Leukemia & lymphoma.

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Cancer.

Approach to frontline therapy in elderly chronic lymphocytic leukemia patients

M. Keating, A. Ferrajoli, O. Benjamini, 2013 .

Chemotherapy of Chronic Lymphocytic Leukemia

M. Keating, S. O'brien, A. Ferrajoli, 2004 .

Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.

E. Estey, Z. Estrov, D. Harris, 1998, Leukemia & lymphoma.

A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure

M. Konopleva, G. Garcia-Manero, T. Kadia, 2019, Leukemia & lymphoma.

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, American journal of hematology.

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3‐ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial: Abstract: AML‐014

M. Konopleva, Z. Estrov, M. Andreeff, 2017 .

Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma

M. Konopleva, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

M. Andreeff, M. Sznol, H. Kantarjian, 2004, Clinical Cancer Research.

Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia

Z. Estrov, M. Keating, S. O'brien, 2021, British journal of haematology.

Treatment of younger patients with chronic lymphocytic leukemia.

A. Ferrajoli, 2010, Hematology. American Society of Hematology. Education Program.

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood Cancer Journal.

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007, Cancer.

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

M. Sznol, H. Kantarjian, G. Garcia-Manero, 2005, Clinical Cancer Research.

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia

Z. Estrov, H. Kantarjian, J. Cortes, 2019, Cancer.

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2006 .

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

H. Kantarjian, G. Garcia-Manero, Koichi Takahashi, 2021, American journal of hematology.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Susan O'Brien, Koji Sasaki, Naveen Pemmaraju, 2018, The Lancet. Haematology.

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.

Naveen Garg, Dominik Wodarz, Xuelin Huang, 2017, JCI insight.

CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia

Z. Estrov, N. Chiorazzi, Xuelin Huang, 2020, Leukemia.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Susan O'Brien, Gautam Borthakur, Marina Konopleva, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, Cancer.

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

G. Daley, H. Kantarjian, J. Cortes, 2004 .

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

Susan O'Brien, Nitin Jain, Z. Estrov, 2015, Blood.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation

Z. Estrov, H. Kantarjian, M. Routbort, 2018, Cancer.

Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Acta Haematologica.

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2013, Blood.

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial

C. Cleeland, Z. Estrov, D. Harris, 2017, The Lancet. Haematology.

A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation

P. Sharma, Z. Estrov, J. Blando, 2018, Blood.

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

K. Do, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Leukemia.

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

E. Estey, H. Kantarjian, G. Garcia-Manero, 2003, Cancer Chemotherapy and Pharmacology.

Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

Z. Estrov, S. Verstovsek, Koichi Takahashi, 2020 .

Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia

D. Kontoyiannis, A. Ferrajoli, P. Strati, 2018, Leukemia & lymphoma.

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic Lymphocytic Leukemia Treatment Options for Patients With Refractory Disease

W. Wierda, A. Ferrajoli, M. Motta, 2009 .

Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2007 .

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

J. Cortes, T. Kadia, M. Keating, 2016, Oncotarget.

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Z. Estrov, E. Shpall, P. Jain, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Z. Estrov, M. Keating, S. O'brien, 2014, Blood.

Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia

M. Keating, S. O'brien, W. Wierda, 2014, Leukemia & lymphoma.

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

M. Keating, S. O'brien, C. Tam, 2013, Cancer.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Z. Estrov, M. Keating, S. O'brien, 2009, Blood.

Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion.

A. Ferrajoli, W. Ding, 2010, Hematology. American Society of Hematology. Education Program.

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

M. Keating, S. O'brien, W. Wierda, 2010, Leukemia research.

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

H. Kantarjian, G. Garcia-Manero, T. Manshouri, 2010, British journal of haematology.

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

K. Coombes, L. Rassenti, T. Kipps, 2009, Blood.

Monoclonal antibodies in chronic lymphocytic leukemia

M. Keating, S. Faderl, A. Ferrajoli, 2006, Expert review of anticancer therapy.

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

Z. Estrov, R. Kanagal-Shamanna, M. Keating, 2022, American journal of hematology.

Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2005 .

Acute Myeloid Leukemia in the Elderly : A Unique Disease November

A. Ferrajoli, 2017 .

Clofarabine combinations as acute myeloid leukemia salvage therapy

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008, Cancer.

Acute Myeloid Leukemia in the Elderly: A Unique Disease

A. Ferrajoli, 2006 .

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.

G. Garcia-Manero, Xuelin Huang, K. Patel, 2022, The Lancet. Haematology.

Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, American journal of hematology.

Cross-Talk between CLL Cells and Bone Marrow Endothelial Cells: Role of Signal Transducer and Activator of Transcription-3

Z. Estrov, D. Harris, C. Bueso-Ramos, 2014 .

Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

Z. Estrov, D. Harris, C. Bueso-Ramos, 2011, Human pathology.

A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia

A. Ferrajoli, 2012, Leukemia & lymphoma.

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

Kim-Anh Do, Susan O'Brien, Jorge Cortes, 2007, Blood.

Multiple‐dose granulocyte‐macrophage–colony‐stimulating factor plus 23‐valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia

D. Musher, M. Keating, S. O'brien, 2008, Cancer.

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

M. Konopleva, M. Andreeff, S. Verstovsek, 2006, Clinical Cancer Research.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

J. Welch, M. Konopleva, M. Andreeff, 2020, Haematologica.

Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases.

J. Cortes, M. Routbort, K. Patel, 2019, JCO precision oncology.

Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors

Z. Estrov, R. Kurzrock, M. Talpaz, 1994, Stem cells.

Growth factors controlling interleukin-4 action on hematopoietic progenitors

Z. Estrov, M. Talpaz, A. Ferrajoli, 1993, Annals of Hematology.

A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia

A. Ferrajoli, J. Randhawa, 2016, Expert review of hematology.

Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies

A. Ferrajoli, D. Rivera, 2022, Current Oncology Reports.

The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia

A. Ferrajoli, C. Vitale, 2020, Expert review of hematology.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

G. Calin, K. Rezvani, Katrien Van Roosbroeck, 2016, Clinical Cancer Research.

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

M. Keating, S. O'brien, J. Burger, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

J. Reuben, Bang‐Ning Lee, S. Kornblau, 2011, Blood.

Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.

M. Suarez‐Almazor, A. Lok, S. Cantor, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19

G. Calin, C. Esposito, V. de Franciscis, 2021, Cancers.

Interferon-α-Induced Biologic Modifications in Patients with Chronic Myelogenous Leukemia

B. Palumbo, A. Liberati, A. Ferrajoli, 1994 .

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Z. Estrov, M. Andreeff, H. Kantarjian, 2006 .

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

M. Andreeff, H. Kantarjian, A. Tsimberidou, 2004, Cancer.

Treatment of chronic lymphocytic leukemia.

S. O'brien, A. Ferrajoli, 2004, Seminars in oncology.

Passive Transfer of Hepatitis B Core Antibody after Intravenous Immunoglobulin Administration in Patients with Cancer: Retrospective Chart Review

M. Suarez‐Almazor, A. Lok, C. Warneke, 2018 .

Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy

M. Suarez‐Almazor, A. Lok, S. Cantor, 2017, Cancer.

Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial

Z. Estrov, H. Kantarjian, M. Keating, 2010 .

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2005 .

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

P. Ganly, S. O'brien, C. Tam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.

Naveen Garg, M. Konopleva, Z. Estrov, 2021, JAMA oncology.

Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors.

I. Wistuba, Z. Estrov, H. Kantarjian, 2020, Blood.

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

G. Borthakur, M. Keating, J. Burger, 2019, Journal of geriatric oncology.

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation

D. Neuberg, L. Rassenti, T. Kipps, 2018, British journal of haematology.

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia

C. Bueso-Ramos, M. Keating, S. O'brien, 2011, Cancer.

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.

Z. Estrov, M. Truong, M. Keating, 2014, Blood.

Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.

A. Rashid, L. Byers, D. Tan, 2020, Leukemia research.

Interferon‐α plus low‐dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients

G. Saglio, E. Morra, M. Lazzarino, 1995, European Journal of Haematology.

EFFECT OF IFNα THERAPY ON SECONDARY Ph1‐POSITIVE CLONES

G. Saglio, A. Liberati, A. Ferrajoli, 1992 .

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2016, Leukemia.

Treatment options for refractory chronic lymphocytic leukemia

A. Ferrajoli, M. Motta, 2012 .

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

H. Kantarjian, M. Keating, S. O'brien, 2011, Blood.

Mediterranean Journal of Hematology and Infectious Diseases Bcr Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

A. Ferrajoli, L. Falchi, J. Baron, 2022 .

Ibrutinib-Associated Cardiovascular Events in a Patient Wearing an Implanted Loop Recorder

Koichi Takahashi, J. Durand, A. Ferrajoli, 2021, Mediterranean journal of hematology and infectious diseases.

M interleukin-1 ( IL-1 ) receptor antagonist and soluble IL-1 receptors Inhibition of acute myelogenous leukemia blast proliferation

E. Estey, D. Harris, R. Kurzrock, 2003 .

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.

E. Estey, P. Bonate, Z. Estrov, 2005, Blood.

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Z. Estrov, J. Reuben, Hui Gao, 2008, Blood.

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience

F. Stingo, Z. Estrov, M. Keating, 2015, British journal of haematology.

Other Cancers in CLL, a Common Problem

A. Ferrajoli, L. Falchi, 2017 .

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.

S. Strom, M. Keating, M. Keating, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

J. Issa, Y. Oki, Z. Estrov, 2007, Blood.

Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches.

F. Grignani, A. Liberati, A. Liberati, 1996, Critical reviews in oncology/hematology.

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2006, Blood.

Chronic Lymphocytic Leukemia

F. Arruga, A. Ferrajoli, T. Vaisitti, 2020, Cancers.

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Zachary B. Abrams, K. Coombes, B. Czerniak, 2019, The Lancet. Oncology.

Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients

Z. Estrov, M. Routbort, K. Patel, 2019, British journal of haematology.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12

R. Foà, S. Molica, A. Cuneo, 2019, Cancers.

Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

L. Abruzzo, M. Keating, S. O'brien, 2015, Clinical lymphoma, myeloma & leukemia.

Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.

K. Coombes, B. Czerniak, Tadeusz Majewski, 2013, The Journal of molecular diagnostics : JMD.

untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously

K. Do, H. Kantarjian, G. Garcia-Manero, 2013 .

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

K. Coombes, B. Czerniak, Tadeusz Majewski, 2011, Blood.

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Susan O'Brien, Alice Lynn, Lynne V Abruzzo, 2008, Blood.

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.

K. Do, H. Kantarjian, P. Mclaughlin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activation of the B‐cell receptor successively activates NF‐κB and STAT3 in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, P. Jain, 2017, International journal of cancer.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of patients with chronic lymphocytic leukemia treated with first‐line idelalisib plus rituximab after cessation of treatment for toxicity

F. Stingo, T. Kadia, M. Keating, 2016, Cancer.

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

F. Stingo, Z. Estrov, H. Kantarjian, 2015, Cancer.

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells

G. Calin, Z. Estrov, D. Harris, 2013, Molecular Cancer.

Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans.

L. Rassenti, T. Kipps, S. Slager, 2012, Blood.

Chronic lymphocytic leukemia in African Americans

J. Weinberg, A. Ferrajoli, L. Falchi, 2012, Leukemia & lymphoma.

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

K. Do, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Evidence‐based Review of Anti‐CD20 Antibody‐containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B‐cell Lymphoma, or Follicular Lymphoma

A. Ferrajoli, I. Jacobs, L. Falchi, 2018, Clinical lymphoma, myeloma & leukemia.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Cancer.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

H. Kantarjian, S. Verstovsek, E. Jabbour, 2019, Leukemia & lymphoma.

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Clinical Cancer Research.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome‐positive chronic myelogenous leukemia in the chronic phase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

microRNA Therapeutics in Cancer — An Emerging Concept

George A. Calin, Anil K Sood, Gabriel Lopez-Berestein, 2016, EBioMedicine.

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

G. Calin, L. Rassenti, T. Kipps, 2013, Blood.

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review

L. Laurenti, A. Ferrajoli, P. Strati, 2018, Haematologica.

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.

H. Kantarjian, J. Cortes, W. Wierda, 2003, Blood.

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

D. Amadori, M. Ferracin, M. Fabbri, 2016, Clinical Cancer Research.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

Treatment of Philadelphia chromosome–positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon‐alpha‐2b and low‐dose cytosine arabinoside

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003, Cancer.

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

M. Keating, S. O'brien, J. Burger, 2015, British journal of haematology.

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).

K. Do, H. Kantarjian, J. Cortes, 2014, Blood.

The involvement of microRNA in the pathogenesis of Richter syndrome

G. Calin, D. Rossi, G. Gaidano, 2018, Haematologica.

Central nervous system Richter’s transformation and parvovirus B19 infection

Lin Pei, Z. Estrov, T. Kadia, 2013, Leukemia & lymphoma.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

G. Borthakur, A. Ferrajoli, M. Siddiqui, 2021, Leukemia research reports.

Lenalidomide in chronic lymphocytic leukemia

A. Ferrajoli, P. Jain, Carrie Anne Orlikowski, 2016 .

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Xiaomin Chen, Z. Estrov, D. Harris, 2010, Blood.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia

M. Keating, S. O'brien, J. Burger, 2018, British journal of haematology.

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

J. Issa, M. Andreeff, H. Kantarjian, 2005 .

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2009 .

β2‐microglobulin normalization within 6 months of ibrutinib‐based treatment is associated with superior progression‐free survival in patients with chronic lymphocytic leukemia

Z. Estrov, M. Keating, S. O'brien, 2016, Cancer.

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens

K. Do, H. Kantarjian, G. Garcia-Manero, 2006, Cancer.

High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.

Z. Estrov, H. Kantarjian, T. Manshouri, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Long-term results of fi rst salvage treatment in CLL patients treated initially with FCR ( fl udarabine , cyclophosphamide , rituximab )

K. Do, H. Kantarjian, J. Cortes, 2014 .

Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia

S. Strom, M. Keating, Xuemei Wang, 2013, Cancer.

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

K. Do, H. Kantarjian, G. Garcia-Manero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia

A. Ferrajoli, C. Vitale, 2018, Haematologica.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

J. Issa, H. Kantarjian, F. Ravandi, 2008, Leukemia & lymphoma.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2014, Clinical lymphoma, myeloma & leukemia.

T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

H. Kantarjian, F. Ravandi, M. Keating, 2007, Leukemia research.

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.

Z. Estrov, D. Harris, S. Verstovsek, 2014, Blood.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Eradication of minimal residual disease in hairy cell leukemia.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2006, Blood.

Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.

M. Keating, C. Tam, D. Kontoyiannis, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Naveen Garg, Rashmi Kanagal-Shamanna, Prithviraj Bose, 2019, The New England journal of medicine.

Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.

M. Suarez‐Almazor, A. Lok, C. Warneke, 2018, The Lancet. Haematology.

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

P. Ganly, S. O'brien, C. Tam, 2022, The New England journal of medicine.

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia

M. Vignali, Z. Estrov, H. Robins, 2017, The Journal of Immunology.

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

H. Kantarjian, J. Cortes, F. Ravandi, 2015, Cancer.

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Blood.

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in‐situ hybridization in 510 patients

Susan O'Brien, Lynne V Abruzzo, Michael J Keating, 2008, British journal of haematology.

Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases

R. Kanagal-Shamanna, J. Burger, A. Ferrajoli, 2019, Leukemia & lymphoma.

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Z. Estrov, H. Kantarjian, P. Jain, 2015, Leukemia & lymphoma.

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma

Michael R. Green, C. Coarfa, K. Bhalla, 2021, Leukemia.

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

E. Estey, Y. Oki, H. Kantarjian, 2006, Blood.

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

J. Byrd, J. Moslehi, J. Pagel, 2021, Haematologica.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.

E. Estey, Z. Estrov, M. Talpaz, 1994, Leukemia.

Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections

G. Calin, S.-C. Jim Yeung, M. Shimizu, 2017, EBioMedicine.

Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.

K. Do, H. Kantarjian, M. Keating, 2005, Blood.

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Z. Estrov, M. Keating, S. O'brien, 2019 .

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

F. Ravandi, A. Pandey, M. Keating, 2012, Leukemia.

Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation

A. Ferrajoli, W. Tong, 2011 .

A phase two study of high dose blinatumomab in Richter’s syndrome

Naveen Garg, M. Andreeff, R. Başar, 2022, Leukemia.

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

P. Sharma, Z. Estrov, J. Blando, 2016 .

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.

H. Kantarjian, J. Cortes, S. Verstovsek, 2007, British journal of haematology.

Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial

M. Konopleva, G. Garcia-Manero, T. Kadia, 2015 .

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2005, Leukemia research.

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia

A. Ferrajoli, Maliha Khan, J. Gibbons, 2017, OncoTargets and therapy.

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.

P. A. Futreal, K. Do, Z. Estrov, 2018, Blood.

Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia

Z. Estrov, M. Keating, S. O'brien, 2015, Cancer.

Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors

T. Kadia, E. Jabbour, L. Medeiros, 2022, Leukemia & lymphoma.

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, T. Manshouri, 2021, Oncotarget.

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Z. Estrov, T. Kadia, G. Borthakur, 2018, Leukemia.

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

M. Keating, S. O'brien, W. Wierda, 2010, Cancer.

Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

Z. Estrov, J. Reuben, Hui Gao, 2011, Cancer.

Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Z. Estrov, H. Kantarjian, J. Reuben, 2009 .

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53

Z. Estrov, H. Kantarjian, K. Patel, 2019, Blood.

Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach

A. Ferrajoli, P. Strati, 2019, Drugs & Aging.

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, M. Andreeff, H. Kantarjian, 2017 .

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Naveen Garg, M. Konopleva, Z. Estrov, 2021, Leukemia.

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Z. Estrov, H. Kantarjian, K. Patel, 2018, Blood.

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, P. Jain, 2018, Oncotarget.

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

Z. Estrov, D. Harris, P. Jain, 2015, Molecular Cancer Research.

Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia.

Z. Estrov, J. Reuben, Hui Gao, 2008 .

Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients.

M. Czuczman, A. Chanan-Khan, M. Keating, 2007 .

STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, M. Keating, 2011, Molecular Cancer Research.

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

E. Kimby, J. Gribben, F. Bosch, 2010 .

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, T. Kadia, M. Keating, 2009 .

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

Z. Estrov, D. Harris, P. Jain, 2018, Leukemia & lymphoma.

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Z. Estrov, H. Kantarjian, P. Jain, 2016 .

Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax

I. Wistuba, M. Konopleva, J. Khoury, 2020, Leukemia & lymphoma.

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).

Z. Estrov, H. Kantarjian, G. Borthakur, 2017 .

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

J. Byrd, J. Moslehi, J. Pagel, 2020 .

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib

A. Ferrajoli, C. Vitale, J. Gibbons, 2021, OncoTargets and therapy.

relapsed and refractory chronic lymphocytic leukemia Lenalidomide induces complete and partial remissions in patients with

Z. Estrov, J. Reuben, Hui Gao, 2013 .

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

M. Keating, S. O'brien, A. Tedeschi, 2003, Cancer.

The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment

Z. Estrov, K. Bhalla, M. Keating, 2019, Leukemia.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

T. Shanafelt, A. Chigaev, L. Sklar, 2018, The Journal of experimental medicine.

Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, H. Kantarjian, S. Kornblau, 2008 .

CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p.

Z. Estrov, H. Kantarjian, M. Keating, 2008 .

Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo

Z. Estrov, D. Harris, P. Jain, 2016 .

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Z. Estrov, H. Kantarjian, N. Daver, 2016 .

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Z. Estrov, H. Kantarjian, N. Daver, 2014 .

High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome

Z. Estrov, H. Kantarjian, P. Jain, 2015, American journal of hematology.

Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia.

B. Palumbo, A. Liberati, A. Ferrajoli, 1994, Journal of Interferon Research.

Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapies

H. Kantarjian, G. Borthakur, M. Keating, 2007, Cancer.

STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage

Z. Estrov, D. Harris, P. Jain, 2019, The Journal of Immunology.

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, BioMed research international.

Signal Transducer and Activator of Transcription (STAT)-3 Activates Nuclear Factor (NF)-κB in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, M. Keating, 2011 .

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, F. Ravandi, E. Jabbour, 2021, Blood.

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Suppression of chronic myelogenous leukemia colony growth by interleukin-4.

Z. Estrov, R. Kurzrock, H. Kantarjian, 1993, Leukemia.

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

M. Konopleva, Z. Estrov, H. Kantarjian, 2008 .

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Z. Estrov, H. Kantarjian, M. Keating, 2010 .

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

M. Keating, S. O'brien, W. Wierda, 2010 .

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.

M. Andreeff, H. Kantarjian, J. Cortes, 2006 .

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

T. Kadia, P. Jain, F. Ravandi, 2020, Leukemia & lymphoma.

The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, S. O'brien, W. Wierda, 2006 .

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2007 .

Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

H. Kantarjian, J. Cortes, S. Verstovsek, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Richter Syndrome in Chronic Lymphocytic Leukemia

A. Ferrajoli, C. Vitale, 2016, Current Hematologic Malignancy Reports.

Lenalidomide Induces Complete and Partial Responses in Patients with Relapsed and Treatment-Refractory Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, J. Reuben, Bang‐Ning Lee, 2006 .

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia research.

Array CGH Analysis of Chronic Lymphocytic Leukemia Reveals Frequent Cryptic Monoallelic and Biallelic Deletions of Chromosome 22q11.

K. Coombes, S. Gunn, L. Abruzzo, 2008 .

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Activity of alemtuzumab in patients with CD52‐positive acute leukemia

G. Garcia-Manero, J. Cortes, S. Verstovsek, 2006, Cancer.

CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

P. Ganly, W. Novotny, C. Tam, 2022, Clinical lymphoma, myeloma & leukemia.

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Z. Estrov, D. Harris, H. Kantarjian, 2007 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Soluble syndecan‐1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, M. Keating, 2009, International journal of laboratory hematology.

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy

A. Pettitt, O. Frankfurt, S. Faderl, 2009, Leukemia.

Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.

K. Bhalla, K. Patel, E. Jabbour, 2023, Pathology.

Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy

T. McDonnell, L. Medeiros, Y. Miao, 2020, American journal of hematology.

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.

H. Tawbi, N. Jain, W. Wierda, 2020, Blood advances.

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, European journal of cancer care.

L‐carnitine and Vitamin B Complex for the Treatment of Pegasparaginase‐induced Hyperbilirubinemia

H. Kantarjian, E. Jabbour, N. Pemmaraju, 2018, Clinical lymphoma, myeloma & leukemia.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, International Journal of Hematology.

Pleural effusions in patients with acute leukemia and myelodysplastic syndrome

R. Morice, L. Bashoura, G. Eapen, 2013, Leukemia & lymphoma.

Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017 .

Role of angiogenesis in chronic lymphocytic leukemia

S. Verstovsek, R. Vrhovac, A. Ferrajoli, 2006, Cancer.

Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.

Steven M Kornblau, Kevin R Coombes, K. Coombes, 2011, Blood.

STAT3-Activated GM-CSFRα Translocates to the Nucleus and Protects CLL Cells from Apoptosis

Z. Estrov, D. Harris, C. Bueso-Ramos, 2014, Molecular Cancer Research.

Genomics STAT 3-Activated GM-CSFR a Translocates to the Nucleus and Protects CLL Cells from Apoptosis

Z. Estrov, D. Harris, C. Bueso-Ramos, 2014 .

61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020

Marina, M. Andreeff, H. Kantarjian, 2020, Indian Journal of Hematology and Blood Transfusion.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

M. Andreeff, G. Garcia-Manero, J. Cortes, 2005 .

FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL).

H. Kantarjian, C. Bueso-Ramos, M. Keating, 2005 .

Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

G. Garcia-Manero, F. Ravandi, M. Keating, 2005 .

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia

M. Keating, S. O'brien, R. Lapushin, 2008, European journal of haematology.

Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

M. Konopleva, H. Kantarjian, J. Cortes, 2007 .

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

Z. Estrov, H. Kantarjian, W. Wierda, 2009 .

Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

Z. Estrov, M. Keating, S. O'brien, 2017, Haematologica.

Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia

D. Berry, E. Estey, J. Wathen, 2003 .

Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).

Z. Estrov, H. Kantarjian, J. Cortes, 2016 .

Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia.

H. Kantarjian, J. Cortes, T. Kadia, 2009 .

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Naveen Garg, Catherine J. Wu, P. Sharma, 2022, Blood advances.

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Naveen Garg, Xiaoping Su, M. Konopleva, 2021, Blood.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.

H. Kantarjian, M. Keating, S. O'brien, 2006 .

Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study

K. Basen-Engquist, E. LaVoy, A. Ferrajoli, 2023, European journal of haematology.

The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL).

J. Reuben, M. Keating, S. O'brien, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab Plus GM-CSF for Patients with Chronic Lymphocytic Leukemia.

H. Kantarjian, M. Keating, S. O'brien, 2005 .

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

H. Kantarjian, J. Cortes, F. Ravandi, 2005 .

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

H. Kantarjian, J. Reuben, Bang‐Ning Lee, 2012 .

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, H. Kantarjian, M. Keating, 2011 .

Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.

J. Burger, N. Jain, W. Wierda, 2023, Leukemia & lymphoma.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Z. Estrov, G. Garcia-Manero, S. Verstovsek, 2007 .

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab

R. Kanagal-Shamanna, M. Keating, N. Jain, 2016, Hematology/oncology and stem cell therapy.

Early Treatment with Ofatumumab in Patients with High-Risk CLL

M. Konopleva, Z. Estrov, T. Kadia, 2022, Blood.

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

G. Borthakur, E. Jabbour, N. Short, 2023, Leukemia & lymphoma.

Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells

Z. Estrov, D. Harris, M. Keating, 2015 .

Symptom profiles in patients with chronic lymphocytic leukemia: validation and application of the M. D. Anderson Symptom Inventory

C. Cleeland, T. Mendoza, M. Keating, 2010 .

Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia

M. Keating, D. Kontoyiannis, W. Wierda, 2013, Leukemia & lymphoma.

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Blood.

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

P. Ganly, S. O'brien, C. Tam, 2022, Blood.

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD

Naveen Garg, T. Kadia, M. Keating, 2023, Leukemia.

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype

Z. Estrov, A. Futreal, Koichi Takahashi, 2019, British journal of haematology.

Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families.

G. Marti, J. Cerhan, N. Camp, 2020, Blood.

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia

M. Keating, M. Kroll, A. Ferrajoli, 2015, Leukemia & lymphoma.

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2006 .

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities.

M. Czuczman, A. Chanan-Khan, M. Keating, 2007 .

Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2 nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, Blood.

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, T. Manshouri, 2022, The Journal of Immunology.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2007, Blood.

Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011 .

Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).

H. Kantarjian, M. Keating, S. O'brien, 2010 .

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008 .

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Naveen Garg, Xiaoping Su, M. Konopleva, 2021, Blood.

A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale

S. Giordano, A. Ferrajoli, Z. Duan, 2023, Blood advances.

Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL.

Z. Estrov, M. Keating, S. O'brien, 2019, Blood.

Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity

J. Burger, N. Jain, C. Peterson, 2023, Cancer.

Bone Marrow (BM) May be More Informative Than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, M. Keating, S. O'brien, 2014 .

Bone Marrow May Be More Informative Than Peripheral Blood To Evaluate Minimal Residual Disease During 1st and 2nd Year Follow Up After First-Line Fludarabine, Cyclophosphamide, and Rituximab For Chronic Lymphocytic Leukemia

Z. Estrov, M. Keating, S. O'brien, 2013 .

Incidence Rate Of Venous Thromboembolism (VTE) and Utilization Of a VTE Prophylaxis Order Set Module In Hospitalized Patients With Leukemia

A. Ferrajoli, Lee Cheng, M. Rodriguez, 2013 .

Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens

Z. Estrov, H. Kantarjian, M. Keating, 2014 .

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2012 .

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2013 .

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).

Naveen Garg, M. Konopleva, Z. Estrov, 2019, Blood.

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2003, Blood.

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

E. Estey, Z. Estrov, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematological Malignancies

Z. Estrov, C. Bueso-Ramos, A. Ferrajoli, 2004, Hematology.

K. Coombes, L. Rassenti, T. Kipps, 2009, Blood.

Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2010 .

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Xiaomin Chen, Z. Estrov, D. Harris, 2010, Blood.

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

M. Keating, S. O'brien, J. Burger, 2014, Haematologica.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Z. Estrov, M. Andreeff, M. Keating, 2019, Blood.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016, British journal of haematology.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

This information is current as Signaling in Chronic Lymphocytic Leukemia Functional Differences between IgM and IgD

Z. Estrov, W. Wierda, T. Oellerich, 2016 .

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

K. Do, H. Kantarjian, G. Garcia-Manero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unusual complications in the management of chronic lymphocytic leukemia

A. Ferrajoli, Max J Gordon, 2022, American journal of hematology.

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.

Z. Estrov, M. Truong, M. Keating, 2014, Blood.

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

M. Keating, S. O'brien, J. Burger, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of younger patients with chronic lymphocytic leukemia.

A. Ferrajoli, 2010, Hematology. American Society of Hematology. Education Program.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

G. Calin, K. Rezvani, Katrien Van Roosbroeck, 2016, Clinical Cancer Research.

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Journal of Clinical Oncology.

How I Manage Chronic Lymphocytic Leukemia

G. Martinelli, A. Ferrajoli, C. Cerchione, 2023, Hematology reports.

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex

Z. Estrov, D. Harris, P. Jain, 2017, Molecular Cancer Research.

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

T. Kipps, M. Keating, S. O'brien, 2015, Leukemia & lymphoma.

Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

A. Ferrajoli, 2009, Leukemia & lymphoma.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2007, Blood.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.

S. O'brien, C. Nabhan, N. Jain, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia.

J. McQuade, J. Wargo, E. Keung, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

CLL-229: Efficacy of Immune Checkpoint Inhibitors in Metastatic Melanoma (MM) Patients with Concurrent Chronic Lymphocytic Leukemia (CLL)

J. Wargo, H. Tawbi, E. Keung, 2020, Clinical Lymphoma Myeloma and Leukemia.

Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene.

M. Routbort, K. Patel, Koichi Takahashi, 2019, Journal of Clinical Oncology.

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY

T. Kadia, F. Ravandi, E. Jabbour, 2023, HemaSphere.

Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

N. Short, A. Ferrajoli, Shouhao Zhou, 2024, PharmacoEconomics.

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

M. Davids, J. Burger, N. Jain, 2024, Blood advances.

An overview of prognostic markers in patients with CLL

A. Ferrajoli, Claudio Cerchione, Julie Braish, 2024, Frontiers in oncology.

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).

K. Do, H. Kantarjian, J. Cortes, 2014, Blood.

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

H. Kantarjian, G. Garcia-Manero, Koichi Takahashi, 2022, American journal of hematology.

Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

M. Konopleva, G. Garcia-Manero, E. Shpall, 2023, American journal of hematology.

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

H. Kantarjian, K. Patel, F. Ravandi, 2024, Leukemia & lymphoma.

A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL ≤ 70 years (yrs).

H. Kantarjian, F. Ravandi, M. Keating, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012 .

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

T. Kadia, M. Keating, N. Jain, 2019, Blood.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

Z. Estrov, A. Wiestner, M. Keating, 2016, Haematologica.

Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma

A. Ferrajoli, L. Nastoupil, Hui Zhao, 2024, JCO clinical cancer informatics.